Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene

Shourong Wu, Nobuhiro Nishiyama, Mitsunobu Kano, Yasuyuki Morishita, Kohei Miyazono, Keiji Itaka, Ung Il Chung, Kazunori Kataoka

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Hypoxia-inducible factor-1 (HIF-1) plays a central role in cellular response to hypoxia by activating vascular endothelial growth factor (VEGF) and other angiogenic factors. Prolyl hydroxylase domain-2 (PHD2) protein induces the degradation of HIF-1 by hydroxylating specific prolyl residues. Therefore gene silencing of PHD2 by RNA interference (RNAi) might increase the expression of angiogenic growth factors and, consequently, neoangiogenesis through the stabilization of HIF-1α. In this study we have shown that the specific silencing of PHD2 is sufficient for stabilizing HIF-1α and increasing its transcriptional activity, resulting in the increased expression of angiogenic factors including VEGF and fibroblast growth factor-2 (FGF2). Moreover, when PHD2-siRNA vector was used, the increase in VEGF secretion was observed for as long as 18 days after transfection. In vitro treatment of human umbilical vein endothelical cells with conditioned medium from PHD2-siRNA vector-transfected NIH3T3 cells was shown to increase cell proliferation. Also, in vivo angiogenesis was observed in mice implanted with Matrigel plugs mixed with NIH3T3 cells transfected with PHD2-siRNA vector. These results indicate that PHD2 silencing induces expressions of multiple angiogenic growth factors by stabilizing HIF-1α, and that the implantation of cells transfected with PHD2-siRNA vector is sufficient to enhance angiogenesis in vivo. In the light of these findings, PHD2 silencing by RNAi might offer a potential tool for angiogenic therapy.

Original languageEnglish
Pages (from-to)1227-1234
Number of pages8
JournalMolecular Therapy
Volume16
Issue number7
DOIs
Publication statusPublished - Jul 2008
Externally publishedYes

Fingerprint

Hypoxia-Inducible Factor-Proline Dioxygenases
Prolyl Hydroxylases
Hypoxia-Inducible Factor 1
Angiogenesis Inducing Agents
Genes
Small Interfering RNA
Vascular Endothelial Growth Factor A
RNA Interference
Intercellular Signaling Peptides and Proteins
Umbilical Veins
Gene Silencing
Fibroblast Growth Factor 2
Conditioned Culture Medium
Proteolysis
Transfection

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. / Wu, Shourong; Nishiyama, Nobuhiro; Kano, Mitsunobu; Morishita, Yasuyuki; Miyazono, Kohei; Itaka, Keiji; Chung, Ung Il; Kataoka, Kazunori.

In: Molecular Therapy, Vol. 16, No. 7, 07.2008, p. 1227-1234.

Research output: Contribution to journalArticle

Wu, S, Nishiyama, N, Kano, M, Morishita, Y, Miyazono, K, Itaka, K, Chung, UI & Kataoka, K 2008, 'Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene', Molecular Therapy, vol. 16, no. 7, pp. 1227-1234. https://doi.org/10.1038/mt.2008.90
Wu, Shourong ; Nishiyama, Nobuhiro ; Kano, Mitsunobu ; Morishita, Yasuyuki ; Miyazono, Kohei ; Itaka, Keiji ; Chung, Ung Il ; Kataoka, Kazunori. / Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. In: Molecular Therapy. 2008 ; Vol. 16, No. 7. pp. 1227-1234.
@article{85a2090aa92049129331aa01eb8df514,
title = "Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene",
abstract = "Hypoxia-inducible factor-1 (HIF-1) plays a central role in cellular response to hypoxia by activating vascular endothelial growth factor (VEGF) and other angiogenic factors. Prolyl hydroxylase domain-2 (PHD2) protein induces the degradation of HIF-1 by hydroxylating specific prolyl residues. Therefore gene silencing of PHD2 by RNA interference (RNAi) might increase the expression of angiogenic growth factors and, consequently, neoangiogenesis through the stabilization of HIF-1α. In this study we have shown that the specific silencing of PHD2 is sufficient for stabilizing HIF-1α and increasing its transcriptional activity, resulting in the increased expression of angiogenic factors including VEGF and fibroblast growth factor-2 (FGF2). Moreover, when PHD2-siRNA vector was used, the increase in VEGF secretion was observed for as long as 18 days after transfection. In vitro treatment of human umbilical vein endothelical cells with conditioned medium from PHD2-siRNA vector-transfected NIH3T3 cells was shown to increase cell proliferation. Also, in vivo angiogenesis was observed in mice implanted with Matrigel plugs mixed with NIH3T3 cells transfected with PHD2-siRNA vector. These results indicate that PHD2 silencing induces expressions of multiple angiogenic growth factors by stabilizing HIF-1α, and that the implantation of cells transfected with PHD2-siRNA vector is sufficient to enhance angiogenesis in vivo. In the light of these findings, PHD2 silencing by RNAi might offer a potential tool for angiogenic therapy.",
author = "Shourong Wu and Nobuhiro Nishiyama and Mitsunobu Kano and Yasuyuki Morishita and Kohei Miyazono and Keiji Itaka and Chung, {Ung Il} and Kazunori Kataoka",
year = "2008",
month = "7",
doi = "10.1038/mt.2008.90",
language = "English",
volume = "16",
pages = "1227--1234",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene

AU - Wu, Shourong

AU - Nishiyama, Nobuhiro

AU - Kano, Mitsunobu

AU - Morishita, Yasuyuki

AU - Miyazono, Kohei

AU - Itaka, Keiji

AU - Chung, Ung Il

AU - Kataoka, Kazunori

PY - 2008/7

Y1 - 2008/7

N2 - Hypoxia-inducible factor-1 (HIF-1) plays a central role in cellular response to hypoxia by activating vascular endothelial growth factor (VEGF) and other angiogenic factors. Prolyl hydroxylase domain-2 (PHD2) protein induces the degradation of HIF-1 by hydroxylating specific prolyl residues. Therefore gene silencing of PHD2 by RNA interference (RNAi) might increase the expression of angiogenic growth factors and, consequently, neoangiogenesis through the stabilization of HIF-1α. In this study we have shown that the specific silencing of PHD2 is sufficient for stabilizing HIF-1α and increasing its transcriptional activity, resulting in the increased expression of angiogenic factors including VEGF and fibroblast growth factor-2 (FGF2). Moreover, when PHD2-siRNA vector was used, the increase in VEGF secretion was observed for as long as 18 days after transfection. In vitro treatment of human umbilical vein endothelical cells with conditioned medium from PHD2-siRNA vector-transfected NIH3T3 cells was shown to increase cell proliferation. Also, in vivo angiogenesis was observed in mice implanted with Matrigel plugs mixed with NIH3T3 cells transfected with PHD2-siRNA vector. These results indicate that PHD2 silencing induces expressions of multiple angiogenic growth factors by stabilizing HIF-1α, and that the implantation of cells transfected with PHD2-siRNA vector is sufficient to enhance angiogenesis in vivo. In the light of these findings, PHD2 silencing by RNAi might offer a potential tool for angiogenic therapy.

AB - Hypoxia-inducible factor-1 (HIF-1) plays a central role in cellular response to hypoxia by activating vascular endothelial growth factor (VEGF) and other angiogenic factors. Prolyl hydroxylase domain-2 (PHD2) protein induces the degradation of HIF-1 by hydroxylating specific prolyl residues. Therefore gene silencing of PHD2 by RNA interference (RNAi) might increase the expression of angiogenic growth factors and, consequently, neoangiogenesis through the stabilization of HIF-1α. In this study we have shown that the specific silencing of PHD2 is sufficient for stabilizing HIF-1α and increasing its transcriptional activity, resulting in the increased expression of angiogenic factors including VEGF and fibroblast growth factor-2 (FGF2). Moreover, when PHD2-siRNA vector was used, the increase in VEGF secretion was observed for as long as 18 days after transfection. In vitro treatment of human umbilical vein endothelical cells with conditioned medium from PHD2-siRNA vector-transfected NIH3T3 cells was shown to increase cell proliferation. Also, in vivo angiogenesis was observed in mice implanted with Matrigel plugs mixed with NIH3T3 cells transfected with PHD2-siRNA vector. These results indicate that PHD2 silencing induces expressions of multiple angiogenic growth factors by stabilizing HIF-1α, and that the implantation of cells transfected with PHD2-siRNA vector is sufficient to enhance angiogenesis in vivo. In the light of these findings, PHD2 silencing by RNAi might offer a potential tool for angiogenic therapy.

UR - http://www.scopus.com/inward/record.url?scp=45749145804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749145804&partnerID=8YFLogxK

U2 - 10.1038/mt.2008.90

DO - 10.1038/mt.2008.90

M3 - Article

C2 - 18500250

AN - SCOPUS:45749145804

VL - 16

SP - 1227

EP - 1234

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 7

ER -